Prescription digital therapeutics company Akili Interactive has licenced a patented technology from Australian digital health company TALi to address early childhood attention impairments.

TALi’s patented technology uses new mechanisms specifically designed to evaluate, target and enhance attention in early childhood aged between three and eight years. It is offered via an engaging video game experience.

Marketed as TALi DETECT (screening) and TALi TRAIN (attention training), the patented technology is presently available in Australia, India, Singapore and Hong Kong.

TALi managing director Glenn Smith said: “Akili is leading the digital therapeutics industry with its ability to dramatically scale into mainstream medicine while maximizing value to patients and to the business, making it an ideal partner for expanding the reach and impact of our technology.”

The deal, which allows Akili to use TALi’s technology in the US, consists of $37.5m in future contingent milestone payments and royalties on potential revenues.

Both companies will focus on executing clinical trials of the TALi technology in paediatric ADHD and seeking regulatory clearance from the US Food and Drug Administration (FDA).

Akili will take the responsibility for the US commercialisation and roll-out of the technology, as per the terms of the deal.

The licencing agreement is expected to enable Akili to expand its presence in prescription digital therapeutics for cognitive impairments.

In addition, it will allow the company to create a path for a new patient demographic to benefit from innovative technologies proven to enhance attention.

Building on Akili’s product portfolio, TALi’s technology is expected to complement the firm’s EndeavorRx, which secured FDA approval to improve attention function in children ages 8-12 with Attention Deficit Hyperactivity Disorder (ADHD).

Akili’s co-founder and CEO Dr Eddie Martucci said: “Akili is continuously seeking opportunities to expand our suite of targeted treatments for cognitive impairments, including through strategic collaborations with companies that share our commitment to delivering high-quality patient experiences built on scientific rigor.”